SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.

Shanghai Bio-heart Biological Technology Co., Ltd.

Equities

2185

CNE100004JH3

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
2.15 ^HKD	+6.44%		+15.59%	-37.13%

Mar. 25	Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor	CI

Shanghai Xinzhi Medical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Shanghai Bio-heart Biological Technology Co., Ltd.

April 13, 2023

Shanghai Xinzhi Medical Technology Co., Ltd. announced a private placement of common shares for the gross proceeds of CNY 15 million on April 14, 2023. The transaction will include participation from new investor Shanghai Bio-heart Biological Technology Co., Ltd. Post completion, Shanghai Bio-heart Biological Technology Co., Ltd. will hold 14.79% stake in exchange for CNY 361,144 of registered capital of the company.

Latest news about Shanghai Bio-heart Biological Technology Co., Ltd.

Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Change of Employee Representative Supervisor	23-08-31	CI
Shanghai Bio-heart Biological Technology's Loss Narrows in H1	23-08-14	MT
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Bioheart Announces Clinical Result for Iberis-Htn At Cit 2023	23-06-29	CI
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Management Changes	23-06-26	CI
Shanghai Bio-heart Injects 15 Million Yuan Into Medical Device Developer Xinzhi Medical; Shares Surge 17%	23-04-16	MT
Shanghai Xinzhi Medical Technology Co., Ltd. announced that it expects to receive CNY 15 million in funding from Shanghai Bio-heart Biological Technology Co., Ltd.	23-04-13	CI
Shanghai Bio-heart Biological Technology Achieves Primary Clinical Endpoint for Catheter System; Shares Climb 44%	23-04-12	MT
Shanghai Bio-heart Biological Technology Co., Ltd. Announces Achievement of Primary Clinical Endpoint in the Iberis-HTN	23-04-11	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Ji Chen Would Not Offer Himself for Re-Election as A Non-Executive Director	23-03-31	CI
Shanghai Bio-heart Biological Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Shanghai Bio-heart Biological Technology Co., Ltd. Announces First Patient Enrollment in the RADIUS-HTN Trial	23-03-27	CI
Shanghai Bio-heart Biological Technology Co., Ltd.(SEHK:2185) dropped from S&P Global BMI Index	23-03-20	CI
Certain H Shares of Shanghai Bio-heart Biological Technology Co., Ltd. are subject to a Lock-Up Agreement Ending on 23-DEC-2022.	22-12-22	CI
Shanghai Bio-heart to Conduct Clinical Trials in Japan for Restenosis Treatment	22-11-17	MT
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Clinical Trial of Sirolimus Drug-Eluting Balloon for the Treatment of In-Stent Restenosis	22-11-17	CI
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Its Iberis® multi-electrode RDN system product Approve by the Ethics Committee of Ruijin Hainan Hospital	22-11-17	CI
Shanghai Bio-heart Biological Technology Gets Chinese Regulator’s Thumbs Up for H Shares	22-10-17	MT
The Core Trust Purchases Shanghai Bio-heart Shares for $31.2 Million	22-09-15	MT
Bio-heart to Infuse $7 Million in Pre-Revenue Medical Device Maker	22-09-06	MT
Bio-Heart Mulls Secondary Listing in Shanghai	22-09-06	MT
Kangdi Tech announced that it has received $7.200000 million in funding from Shanghai Bio-heart Biological Technology Co., Ltd. and other investors.	22-09-05	CI
Shanghai Bio-heart Biological's Clinical Trials for Rapamycin-Eluting Scaffold Achieves Primary Clinical Endpoint	22-08-17	MT
Shanghai Bio-Heart Biological Technology Co., Ltd. Announces Achievement of Pre-Set Primary Clinical Endpoint in the RCT of Bioheart Bioresorbable Coronary Rapamycin-Eluting Scaffold in Patients With Coronary Heart Disease	22-08-16	CI

Chart Shanghai Bio-heart Biological Technology Co., Ltd.

Duration

Period

Chart Shanghai Bio-heart Biological Technology Co., Ltd.

More charts

Company Profile

Shanghai Bio-Heart Biological Technology Co Ltd is a China-based company mainly engaged in interventional instruments. The Company's main businesses are the development and production of interventional cardiovascular devices. The Company's main products include fully bioresorbable scaffolds (BRS) and renal denervation (RDN). The Company's products are mainly used to meet medical needs for the treatment of coronary, peripheral artery disease and hypertension.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-01 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.02

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
SHANGHAI BIO-HEART BIOLOGICAL TECHNOLOGY CO., LTD.	-37.13%	62.81M
STRYKER CORPORATION	+13.43%	128B
SMITH & NEPHEW PLC	-8.76%	10.65B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	+0.91%	8.82B
INSPIRE MEDICAL SYSTEMS, INC.	+18.98%	7.19B
GLAUKOS CORPORATION	+21.54%	4.99B
AXONICS, INC.	+7.63%	3.4B
ENOVIS CORPORATION	+0.12%	3.03B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-4.80%	2.14B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-4.72%	2B

Medical Devices & Implants